Evidence

Discover our latest testimonials and publications

Testimonials

Dr. Carlo Brugnara -Director, Hematology Lab

Boston Children's Hospital - Boston, US
OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms and beyond.

Dr. Steven Melnick -Chief, Department of Pathology

Nicklaus Children's Hospital - Miami, US
To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs.

Pamala Travis -Technical Specialist for Point of Care

University of Cincinnati Medical Center - Ohio, US
OLO makes CBC testing a reality at UC Health. I am impressed with the 5-part diff accuracy and the 10 minutes turnaround time. All it takes is 2 drops of blood in one cuvette, without any wet consumables. Best of all, no calibration or maintenance. It's truly a game changer.

Dr. Alan Nye -Executive Director, Pennine MSK Partnership

Oldham Integrated Care Centre - Manchester, UK
Thanks to OLO and the use of POC we were able to create a new patient pathway to treat vulnerable non-COVID-19 patients away from the main Oldham hospital. The training we did to learn how to use OLO was straightforward and comprehensive. OLO is an intuitive machine with on-screen step by step instructions which makes the process easy to remember. In addition, the OLO rejects samples that are not properly prepared and explains what went wrong, which helps us learn and improve. OLO also doesn’t require any maintenance, a game changer allowing us more time to care for patients.

Dr. Ram Doolman -Director, Laboratories Division & Automated Mega-Laboratory

Sheba Tel Hashomer Medical Center - Tel Aviv, ISR
The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19.

Dr. David B. Wheat MD -Physician, POL

Clinton Family Care - Mississippi, USA
The number one reason to deploy OLO was to reduce overhead cost. With OLO, we do not need to manage all the reagents, diluents and cleaning supplies, in addition to the quality control materials, which can be quite a lot of administrative work for a lean staff like ours. The real value is customer service, and Sight is just exceptional. It’s so far beyond anything I’ve seen in the industry.
Read More

Ian Smith -Screening Laboratory and Point of Care Testing Manager

Oxford University Hospitals NHS Foundation Trust - Oxford, UK
One of the main benefits of Sight OLO is that it’s easy to maintain. Because it has a cartridge-based system that stores all the reagents within a single cartridge, it doesn’t require buffer packs or calibrations that may require further maintenance. Adding Sight OLO to our armory of point-of-care diagnostics can both improve and expedite the treatment decision process for our healthcare providers.

Publications and Regulatory Submissions

OLO is listed in the ARTG (Australian Register of Therapeutic Goods)
July, 20th 2020
Received Canada Class II Medical Device License
March, 29th 2021
FDA 510 (k) Clearance
November, 1st 2019
OLO is listed in the Registry of Medical Devices and Accessories in Israel  
Approved by ANVISA (the National Health Surveillance Agency in Brazil)
Meet the team behind Sight